Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 236

1.

Conditionally ablated Pten in prostate basal cells promotes basal-to-luminal differentiation and causes invasive prostate cancer in mice.

Lu TL, Huang YF, You LR, Chao NC, Su FY, Chang JL, Chen CM.

Am J Pathol. 2013 Mar;182(3):975-91. doi: 10.1016/j.ajpath.2012.11.025. Epub 2013 Jan 9.

PMID:
23313138
2.

Differential requirements for β-catenin in murine prostate cancer originating from basal versus luminal cells.

Lu TL, Chen CM.

J Pathol. 2015 Jul;236(3):290-301. doi: 10.1002/path.4521. Epub 2015 Apr 8.

PMID:
25712462
3.

Accumulating progenitor cells in the luminal epithelial cell layer are candidate tumor initiating cells in a Pten knockout mouse prostate cancer model.

Korsten H, Ziel-van der Made A, Ma X, van der Kwast T, Trapman J.

PLoS One. 2009 May 22;4(5):e5662. doi: 10.1371/journal.pone.0005662.

4.

Lineage analysis of basal epithelial cells reveals their unexpected plasticity and supports a cell-of-origin model for prostate cancer heterogeneity.

Wang ZA, Mitrofanova A, Bergren SK, Abate-Shen C, Cardiff RD, Califano A, Shen MM.

Nat Cell Biol. 2013 Mar;15(3):274-83. doi: 10.1038/ncb2697. Epub 2013 Feb 24.

5.

A luminal epithelial stem cell that is a cell of origin for prostate cancer.

Wang X, Kruithof-de Julio M, Economides KD, Walker D, Yu H, Halili MV, Hu YP, Price SM, Abate-Shen C, Shen MM.

Nature. 2009 Sep 24;461(7263):495-500. doi: 10.1038/nature08361. Epub 2009 Sep 9.

6.

Temporally controlled ablation of PTEN in adult mouse prostate epithelium generates a model of invasive prostatic adenocarcinoma.

Ratnacaram CK, Teletin M, Jiang M, Meng X, Chambon P, Metzger D.

Proc Natl Acad Sci U S A. 2008 Feb 19;105(7):2521-6. doi: 10.1073/pnas.0712021105. Epub 2008 Feb 11.

7.

PTEN deletion and heme oxygenase-1 overexpression cooperate in prostate cancer progression and are associated with adverse clinical outcome.

Li Y, Su J, DingZhang X, Zhang J, Yoshimoto M, Liu S, Bijian K, Gupta A, Squire JA, Alaoui Jamali MA, Bismar TA.

J Pathol. 2011 May;224(1):90-100. doi: 10.1002/path.2855. Epub 2011 Mar 7.

PMID:
21381033
8.

Conditional deletion of the Pten gene in the mouse prostate induces prostatic intraepithelial neoplasms at early ages but a slow progression to prostate tumors.

Kwak MK, Johnson DT, Zhu C, Lee SH, Ye DW, Luong R, Sun Z.

PLoS One. 2013;8(1):e53476. doi: 10.1371/journal.pone.0053476. Epub 2013 Jan 8.

9.

Self-renewing Pten-/- TP53-/- protospheres produce metastatic adenocarcinoma cell lines with multipotent progenitor activity.

Abou-Kheir W, Hynes PG, Martin P, Yin JJ, Liu YN, Seng V, Lake R, Spurrier J, Kelly K.

PLoS One. 2011;6(10):e26112. doi: 10.1371/journal.pone.0026112. Epub 2011 Oct 11.

10.

Identification of CD166 as a surface marker for enriching prostate stem/progenitor and cancer initiating cells.

Jiao J, Hindoyan A, Wang S, Tran LM, Goldstein AS, Lawson D, Chen D, Li Y, Guo C, Zhang B, Fazli L, Gleave M, Witte ON, Garraway IP, Wu H.

PLoS One. 2012;7(8):e42564. doi: 10.1371/journal.pone.0042564. Epub 2012 Aug 3.

11.

Targeted biallelic inactivation of Pten in the mouse prostate leads to prostate cancer accompanied by increased epithelial cell proliferation but not by reduced apoptosis.

Ma X, Ziel-van der Made AC, Autar B, van der Korput HA, Vermeij M, van Duijn P, Cleutjens KB, de Krijger R, Krimpenfort P, Berns A, van der Kwast TH, Trapman J.

Cancer Res. 2005 Jul 1;65(13):5730-9.

12.

Characterizing the contribution of stem/progenitor cells to tumorigenesis in the Pten-/-TP53-/- prostate cancer model.

Abou-Kheir WG, Hynes PG, Martin PL, Pierce R, Kelly K.

Stem Cells. 2010 Dec;28(12):2129-40. doi: 10.1002/stem.538.

13.

Loss of Nkx3.1 leads to the activation of discrete downstream target genes during prostate tumorigenesis.

Song H, Zhang B, Watson MA, Humphrey PA, Lim H, Milbrandt J.

Oncogene. 2009 Sep 17;28(37):3307-19. doi: 10.1038/onc.2009.181. Epub 2009 Jul 13.

14.

Prostatic inflammation enhances basal-to-luminal differentiation and accelerates initiation of prostate cancer with a basal cell origin.

Kwon OJ, Zhang L, Ittmann MM, Xin L.

Proc Natl Acad Sci U S A. 2014 Feb 4;111(5):E592-600. doi: 10.1073/pnas.1318157111. Epub 2013 Dec 23.

15.

BTG2 loss and miR-21 upregulation contribute to prostate cell transformation by inducing luminal markers expression and epithelial-mesenchymal transition.

Coppola V, Musumeci M, Patrizii M, Cannistraci A, Addario A, Maugeri-Saccà M, Biffoni M, Francescangeli F, Cordenonsi M, Piccolo S, Memeo L, Pagliuca A, Muto G, Zeuner A, De Maria R, Bonci D.

Oncogene. 2013 Apr 4;32(14):1843-53. doi: 10.1038/onc.2012.194. Epub 2012 May 21.

PMID:
22614007
16.

SMAD4-dependent barrier constrains prostate cancer growth and metastatic progression.

Ding Z, Wu CJ, Chu GC, Xiao Y, Ho D, Zhang J, Perry SR, Labrot ES, Wu X, Lis R, Hoshida Y, Hiller D, Hu B, Jiang S, Zheng H, Stegh AH, Scott KL, Signoretti S, Bardeesy N, Wang YA, Hill DE, Golub TR, Stampfer MJ, Wong WH, Loda M, Mucci L, Chin L, DePinho RA.

Nature. 2011 Feb 10;470(7333):269-73. doi: 10.1038/nature09677. Epub 2011 Feb 2.

17.

The pace of prostatic intraepithelial neoplasia development is determined by the timing of Pten tumor suppressor gene excision.

Luchman HA, Benediktsson H, Villemaire ML, Peterson AC, Jirik FR.

PLoS One. 2008;3(12):e3940. doi: 10.1371/journal.pone.0003940. Epub 2008 Dec 15.

18.

Slow disease progression in a C57BL/6 pten-deficient mouse model of prostate cancer.

Svensson RU, Haverkamp JM, Thedens DR, Cohen MB, Ratliff TL, Henry MD.

Am J Pathol. 2011 Jul;179(1):502-12. doi: 10.1016/j.ajpath.2011.03.014. Epub 2011 May 7.

19.

Prostate cancer stem cells: do they have a basal or luminal phenotype?

Maitland NJ, Frame FM, Polson ES, Lewis JL, Collins AT.

Horm Cancer. 2011 Feb;2(1):47-61. doi: 10.1007/s12672-010-0058-y.

PMID:
21761340
20.
Items per page

Supplemental Content

Write to the Help Desk